mesalamine has been researched along with Colitis, Lymphocytic in 8 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
Colitis, Lymphocytic: A subtype of MICROSCOPIC COLITIS, characterized by chronic watery DIARRHEA of unknown origin, a normal COLONOSCOPY but abnormal histopathology on BIOPSY. Microscopic examination of biopsy samples taken from the COLON show infiltration of LYMPHOCYTES in the superficial EPITHELIUM and the underlying connective tissue (lamina propria).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The incidence of adverse events was 47." | 2.87 | Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis. ( Armerding, P; Aust, D; Böhm, G; Bonderup, O; Fernández-Bañares, F; Greinwald, R; Kupcinskas, J; Miehlke, S; Mihaly, E; Münch, A; Munck, LK; Nacak, T; Rehbehn, KU, 2018) |
| "Microscopic colitis is a common cause of chronic watery diarrhea with a great impact on patient quality of life." | 2.66 | Treatment of microscopic colitis: the role of budesonide and new alternatives for refractory patients. ( Casanova, MJ; Gisbert, JP; Rojo, E, 2020) |
| "Lymphocytic colitis is a cause of chronic diarrhea." | 2.55 | Interventions for treating lymphocytic colitis. ( Al Yatama, N; Bhanji, T; Chande, N; MacDonald, JK; McDonald, JW; Nguyen, TM, 2017) |
| "Lymphocytic colitis is a cause of chronic diarrhea." | 2.44 | Interventions for treating lymphocytic colitis. ( Chande, N; Macdonald, JK; McDonald, JW, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Rojo, E | 1 |
| Casanova, MJ | 1 |
| Gisbert, JP | 1 |
| Chande, N | 2 |
| Al Yatama, N | 1 |
| Bhanji, T | 1 |
| Nguyen, TM | 1 |
| McDonald, JW | 2 |
| MacDonald, JK | 2 |
| Setia, N | 1 |
| Alpert, L | 1 |
| van der Sloot, KW | 1 |
| Colussi, D | 1 |
| Stewart, KO | 1 |
| Misdraji, J | 1 |
| Khalili, H | 1 |
| Lauwers, GY | 1 |
| Miehlke, S | 1 |
| Aust, D | 1 |
| Mihaly, E | 1 |
| Armerding, P | 1 |
| Böhm, G | 1 |
| Bonderup, O | 1 |
| Fernández-Bañares, F | 1 |
| Kupcinskas, J | 1 |
| Munck, LK | 1 |
| Rehbehn, KU | 1 |
| Nacak, T | 1 |
| Greinwald, R | 1 |
| Münch, A | 1 |
| Pardi, DS | 1 |
| Calabrese, C | 1 |
| Gionchetti, P | 1 |
| Liguori, G | 1 |
| Areni, A | 1 |
| Fornarini, GS | 1 |
| Campieri, M | 1 |
| Rizzello, F | 1 |
| Halbritter, J | 1 |
| Wittenburg, H | 1 |
| Schiefke, I | 1 |
| Amann, K | 1 |
| Lindner, T | 1 |
| Rasche, FM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Double-dummy, Randomised, Placebo-controlled, Multi-centre Phase III Study on the Efficacy and Tolerability of a 8-week Treatment With Budesonide vs. Mesalazine vs. Placebo in Patients With Lymphocytic Colitis[NCT01209208] | Phase 3 | 57 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for mesalamine and Colitis, Lymphocytic
| Article | Year |
|---|---|
Treatment of microscopic colitis: the role of budesonide and new alternatives for refractory patients.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antidiarrheals; Antimetabolites; Azathioprine; Bi | 2020 |
Interventions for treating lymphocytic colitis.
Topics: Anti-Inflammatory Agents; Antidiarrheals; Beclomethasone; Bismuth; Budesonide; Cholestyramine Resin; | 2017 |
Diagnosis and Management of Microscopic Colitis.
Topics: Anion Exchange Resins; Anti-Inflammatory Agents, Non-Steroidal; Antidiarrheals; Autoimmunity; Bile A | 2017 |
Interventions for treating lymphocytic colitis.
Topics: Antidiarrheals; Bismuth; Budesonide; Cholestyramine Resin; Colitis, Lymphocytic; Humans; Mesalamine; | 2008 |
2 trials available for mesalamine and Colitis, Lymphocytic
| Article | Year |
|---|---|
Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Budesonide; Colitis, Lymphocytic; Double-Blind Metho | 2018 |
Clinical course of microscopic colitis in a single-center cohort study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Cholestyramine Resin; Coho | 2011 |
2 other studies available for mesalamine and Colitis, Lymphocytic
| Article | Year |
|---|---|
Lymphocytic colitis: pathologic predictors of response to therapy.
Topics: Adult; Aged; Aged, 80 and over; Antidiarrheals; Biopsy; Bismuth; Colitis, Lymphocytic; Collagen; Fem | 2018 |
MPA: a treatment option for lymphocytic colitis and mesalamine-induced interstitial nephritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Lymphocytic; Enzyme Inhibitors; Humans; Male; Mesa | 2012 |